HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Francisco G Medina-Rodriguez Selected Research

CT-P10

12/2019Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.
2/2019Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial.
8/2018Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
8/2017Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.
3/2017A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis.
1/2017Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Francisco G Medina-Rodriguez Research Topics

Disease

6Rheumatoid Arthritis
12/2019 - 01/2017
1Necrosis
03/2017

Drug/Important Bio-Agent (IBA)

6Rituximab (Mabthera)FDA Link
12/2019 - 01/2017
6CT-P10IBA
12/2019 - 01/2017
5Biosimilar PharmaceuticalsIBA
12/2019 - 01/2017
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/2017

Therapy/Procedure

1Biological Therapy
08/2017